Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE
Laboratorios LICONSA, S.A.
50/12.5 Milligram
Film Coated Tablet
2008-05-02
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Losartan Potassium/Hydrochlorothiazide Liconsa 50 mg/12.5 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of losartan potassium, equivalent to 45.76 mg of losartan, and 12.5 mg of hydrochlorothiazide. Excipient: 70.31 mg of lactose monohydrate/film-coated tablet. For a full list of exipients see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Round, yellow, film-coated tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on hydrochlorothiazide or losartan monotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Method of administration_ The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). Losartan potassium/Hydrochlorothiazide may be administered with or without food. Where possible, titration with the individual components (i.e. losartan and hydrochlorothiazide) is recommended. When clinically appropriate direct change from monotherapy with losartan 50 mg or hydrochlorothiazide 12.5 mg to the fixed combination may be considered in patients whose blood pressure is not adequately controlled. The usual starting and maintenance dose is 1 tablet once daily for most patients. For patients who do not respond adequately, the dosage may be increased to 2 tablets once daily. The maximum dose is 2 tablets once daily. In general, the antihypertensive effect is attained within three to four weeks after initiation of therapy. _Use in the elderly: _No initial dose adjustment is necessary. Experience is limited in this population. _Use in renal impairment_: No initial dosage adjustment is necessary in patients with mild to moderate rena Baca dokumen lengkapnya